Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Opioid dependence (DSM-IV TR)~* Age 18 or above~* Applied \& Approved for Norway's national OMT program~* Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient treatment or correctional (prison) facility~* Voluntarily seeking treatment for opioid dependence~Exclusion Criteria:~* Pregnant or breast-feeding~* Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality~* Serious debilitation of liver or renal function (e.g. Child-Pugh level C)~* Use of excluded medication~* Known intolerance to study drugs or their ingredients~* Employment in firm manufacturing one of the study drugs or close relation to such person

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naltrexone intramuscular suspension (Type: EXPERIMENTAL): Extended release naltrexone injections 380mg
- Buprenorphine-naloxone (Type: ACTIVE_COMPARATOR): Flexible oral dose 4-24 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).